Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.

The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice

Open access

Published version of a preprint

Abstract

Ageing-associated functional decline of organs and increased risk for age-related chronic pathologies is driven in part by the accumulation of senescent cells, which develop the senescence-associated secretory phenotype (SASP). Here we show that procyanidin C1 (PCC1), a polyphenolic component of grape seed extract (GSE), increases the healthspan and lifespan of mice through its action on senescent cells. By screening a library of natural products, we find that GSE, and PCC1 as one of its active components, have specific effects on senescent cells. At low concentrations, PCC1 appears to inhibit SASP formation, whereas it selectively kills senescent cells at higher concentrations, possibly by promoting production of reactive oxygen species and mitochondrial dysfunction. In rodent models, PCC1 depletes senescent cells in a treatment-damaged tumour microenvironment and enhances therapeutic efficacy when co-administered with chemotherapy. Intermittent administration of PCC1 to either irradiated, senescent cell-implanted or naturally aged old mice alleviates physical dysfunction and prolongs survival. We identify PCC1 as a natural senotherapeutic agent with in vivo activity and high potential for further development as a clinical intervention to delay, alleviate or prevent age-related pathologies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42255-021-00491-8

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Characterisation of the capacity of GSE to eliminate senescent cells. a, Quantification of senescent PSC27 cell survival by SA-β-Gal positivity. GSE was applied to the medium at increasing concentrations. CTRL, control (proliferating) cells; SEN, senescent cells; NS, not significant. P values were calculated by one-way ANOVA with Tukey’s multiple-comparison test. b, Representative images displaying SA-β-Gal staining after treatment of PSC27 cells with different concentrations of GSE. Scale bar, 20 μm. Data are representative of three independent experiments. DMSO, dimethylsulphoxide. c, Survival analysis of control and senescent PSC27 cells upon treatment with GSE (at concentrations of 0.3750, 0.7500, 1.8750, 3.7500, 7.5000 and 15.0000 μg ml−1, respectively). Data are shown as mean ± s.d. and were derived from three biological replicates (n = 3 independent assays). P values were calculated by two-sided t-tests. d, Time course measurement of in vitro viability upon treatment of control and senescent PSC27 cells with GSE (3.75 μg ml−1). Data are shown as mean ± s.d. and were derived from three biological replicates (n = 3 independent experiments). P values were calculated by two-sided t-tests. e, Flow cytometry measurement of control and senescent PSC27 cells after processing with an annexin V–FITC and propidium iodide (PI) kit and 4,6-diamidino-2-phenylindole (DAPI) staining to determine the extent of apoptosis. Q1–Q4, quartiles 1–4. f, Comparative quantification of the percentage of viable (Q4, PI−annexin V−) and apoptotic (Q2 and Q3, PI+annexin V+ and PI−annexin V+, respectively) cells in control or senescent populations treated with vehicle or GSE for 3 d (n = 3 biologically independent assays). P values were calculated by two-sided t-tests. g, Measurement of the fluorescence signal of MitoSOX Red, a mitochondrial superoxide indicator, in PSC27 cells under different conditions. P values were calculated by two-sided t-tests. h, High-resolution mass spectra showing the total ion chromatogram (TIC) and base peak chromatogram of GSE after performing HPLC–ESI-QTOF-MS. Unless otherwise indicated, cells were subjected to relevant analyses 3 d after GSE treatment in the culture condition. cps, counts per second. Data in bar graphs and regression curves are shown as mean ± s.d. and are representative of three biological replicates. NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Source data
Fig. 1 Characterisation of the capacity of GSE to eliminate senescent cells. a, Quantification of senescent PSC27 cell survival by SA-β-Gal positivity. GSE was applied to the medium at increasing concentrations. CTRL, control (proliferating) cells; SEN, senescent cells; NS, not significant. P values were calculated by one-way ANOVA with Tukey’s multiple-comparison test. b, Representative images displaying SA-β-Gal staining after treatment of PSC27 cells with different concentrations of GSE. Scale bar, 20 μm. Data are representative of three independent experiments. DMSO, dimethylsulphoxide. c, Survival analysis of control and senescent PSC27 cells upon treatment with GSE (at concentrations of 0.3750, 0.7500, 1.8750, 3.7500, 7.5000 and 15.0000 μg ml−1, respectively). Data are shown as mean ± s.d. and were derived from three biological replicates (n = 3 independent assays). P values were calculated by two-sided t-tests. d, Time course measurement of in vitro viability upon treatment of control and senescent PSC27 cells with GSE (3.75 μg ml−1). Data are shown as mean ± s.d. and were derived from three biological replicates (n = 3 independent experiments). P values were calculated by two-sided t-tests. e, Flow cytometry measurement of control and senescent PSC27 cells after processing with an annexin V–FITC and propidium iodide (PI) kit and 4,6-diamidino-2-phenylindole (DAPI) staining to determine the extent of apoptosis. Q1–Q4, quartiles 1–4. f, Comparative quantification of the percentage of viable (Q4, PI−annexin V−) and apoptotic (Q2 and Q3, PI+annexin V+ and PI−annexin V+, respectively) cells in control or senescent populations treated with vehicle or GSE for 3 d (n = 3 biologically independent assays). P values were calculated by two-sided t-tests. g, Measurement of the fluorescence signal of MitoSOX Red, a mitochondrial superoxide indicator, in PSC27 cells under different conditions. P values were calculated by two-sided t-tests. h, High-resolution mass spectra showing the total ion chromatogram (TIC) and base peak chromatogram of GSE after performing HPLC–ESI-QTOF-MS. Unless otherwise indicated, cells were subjected to relevant analyses 3 d after GSE treatment in the culture condition. cps, counts per second. Data in bar graphs and regression curves are shown as mean ± s.d. and are representative of three biological replicates. NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Source dataCC BY · PubMed Central
Fig. 2 Characterisation of the senolytic potential of PCC1. a, Measurement of senescent PSC27 cell survival by SA-β-Gal staining. PCC1 was applied at increasing concentrations. P values were calculated by one-way ANOVA with Tukey’s multiple-comparison test. b, Survival of senescent PSC27 cells induced by bleomycin at increasing PCC1 concentrations. c, Apoptotic assay for caspase 3/7 activity. d, Time course survival curves to assess PSC27 cell viability after PCC1 treatment. e, Images of SA-β-Gal staining. TIS, therapy-induced senescence (by bleomycin). Scale bar, 20 μm. Data are representative of three independent experiments. f, Flow cytometry after processing with an annexin V–FITC and PI kit and DAPI staining to determine apoptosis levels. g, Quantification of the percentage of viable (Q4, PI−annexin V−) and apoptotic (Q2 and Q3, PI+annexin V+ and PI−annexin V+, respectively) cells after treatment with vehicle or PCC1 for 3 d (n = 3 biologically independent assays). h, Immunofluorescence staining of PSC27 cells. RS was induced by serial passaging before PCC1 treatment. Red, p16INK4a. Cells at an early passage (P10) were used as a negative control. ABT-263 (1.25 μM) was tested as a positive control. Scale bar, 20 μm. i, Statistics of immunofluorescence staining. j, PCC1-induced senolytic activity after pan-caspase inhibition (20 μM QVD-OPh). k, PD assay of human MSCs. PCC1 was applied on the 8th day after the beginning of experiments as indicated. BLEO, bleomycin. For c,d,k, data are shown as mean ± s.d. and were derived from three biological replicates (n = 3 independent assays). For data in b–d,g,i,j, P values were calculated by two-sided t-tests. In experiments for c–k, PCC1 was used at 100 μM. Unless otherwise indicated, samples were collected for analyses 3 d after PCC1 treatment. Data in bar graphs are shown as mean ± s.d. and are representative of three biological replicates. NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Source data
Fig. 2 Characterisation of the senolytic potential of PCC1. a, Measurement of senescent PSC27 cell survival by SA-β-Gal staining. PCC1 was applied at increasing concentrations. P values were calculated by one-way ANOVA with Tukey’s multiple-comparison test. b, Survival of senescent PSC27 cells induced by bleomycin at increasing PCC1 concentrations. c, Apoptotic assay for caspase 3/7 activity. d, Time course survival curves to assess PSC27 cell viability after PCC1 treatment. e, Images of SA-β-Gal staining. TIS, therapy-induced senescence (by bleomycin). Scale bar, 20 μm. Data are representative of three independent experiments. f, Flow cytometry after processing with an annexin V–FITC and PI kit and DAPI staining to determine apoptosis levels. g, Quantification of the percentage of viable (Q4, PI−annexin V−) and apoptotic (Q2 and Q3, PI+annexin V+ and PI−annexin V+, respectively) cells after treatment with vehicle or PCC1 for 3 d (n = 3 biologically independent assays). h, Immunofluorescence staining of PSC27 cells. RS was induced by serial passaging before PCC1 treatment. Red, p16INK4a. Cells at an early passage (P10) were used as a negative control. ABT-263 (1.25 μM) was tested as a positive control. Scale bar, 20 μm. i, Statistics of immunofluorescence staining. j, PCC1-induced senolytic activity after pan-caspase inhibition (20 μM QVD-OPh). k, PD assay of human MSCs. PCC1 was applied on the 8th day after the beginning of experiments as indicated. BLEO, bleomycin. For c,d,k, data are shown as mean ± s.d. and were derived from three biological replicates (n = 3 independent assays). For data in b–d,g,i,j, P values were calculated by two-sided t-tests. In experiments for c–k, PCC1 was used at 100 μM. Unless otherwise indicated, samples were collected for analyses 3 d after PCC1 treatment. Data in bar graphs are shown as mean ± s.d. and are representative of three biological replicates. NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Source dataCC BY · PubMed Central
Fig. 3 PCC1 induces senescent cell apoptosis by engaging pro-apoptotic pathways. a, Chemical structure of the trimeric epicatechin PCC1. b, Heatmap depicting top genes (50) significantly upregulated in senescent PSC27 cells but downregulated upon PCC1 treatment (50 μM). Red stars, SASP factors. c, GSEA plot of a significant gene set in the SASP spectrum. FDR, false discovery rate; NES, normalized enrichment score. d, GSEA plot of a significant gene set associated with NF-κB-mediated signalling. e, NetworkAnalyst map of protein–protein interactions of typical SASP-associated factors significantly upregulated in senescent cells but downregulated by PCC1 treatment. f, Heatmap showing the differential expression of BCL-2 family genes in control, senescent and PCC1-treated senescent cells. g, Immunoblot of PSC27 cells exposed to different agents. Expression of pro-apoptotic and anti-apoptotic factors and DDR signalling-associated molecules was examined. Caspase 3 (t), total caspase 3; caspase 3 (c), cleaved caspase 3; p, phosphorylated. β-actin and GAPDH, loading controls. Data are representative of three independent experiments. h, Cells were infected with three different short hairpin RNA species targeting NOXA or PUMA before being exposed to bleomycin to induce senescence. Seven days later, cells were treated with PCC1 (100 μM) for a 3-d period to induce apoptosis. SCR, scramble. i, NOXA expression was determined using quantitative PCR with reverse transcription (RT–qPCR). Cells were treated with bleomycin to induce senescence before exposure to 100 μM PCC1 for 3 d in the absence or presence of 10 μM MK2206, 10 μM ruxolitinib or 20 nM BMS-582949 to inhibit the activity of AKT, JAK1 and/or JAK2 or p38 MAPK, respectively. j, A similar set of RT–qPCR expression assays for PUMA using conditions described in i. k–m, Measurement of cell viability after PCC1 treatment in the absence or presence of MK2206 (k), ruxolitinib (l) or BMS-582949 (m), included to inhibit the enzymatic activity of AKT, JAK1 and/or JAK2 or p38 MAPK, respectively. For data in c,d, P values were calculated by one-way ANOVA with Tukey’s post hoc comparison. Statistical significance in h–m was calculated using two-sided t-tests or one-way ANOVA (Dunnett’s test). Data in all bar graphs are shown as mean ± s.d. and represent three biological replicates. NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Source data
Fig. 3 PCC1 induces senescent cell apoptosis by engaging pro-apoptotic pathways. a, Chemical structure of the trimeric epicatechin PCC1. b, Heatmap depicting top genes (50) significantly upregulated in senescent PSC27 cells but downregulated upon PCC1 treatment (50 μM). Red stars, SASP factors. c, GSEA plot of a significant gene set in the SASP spectrum. FDR, false discovery rate; NES, normalized enrichment score. d, GSEA plot of a significant gene set associated with NF-κB-mediated signalling. e, NetworkAnalyst map of protein–protein interactions of typical SASP-associated factors significantly upregulated in senescent cells but downregulated by PCC1 treatment. f, Heatmap showing the differential expression of BCL-2 family genes in control, senescent and PCC1-treated senescent cells. g, Immunoblot of PSC27 cells exposed to different agents. Expression of pro-apoptotic and anti-apoptotic factors and DDR signalling-associated molecules was examined. Caspase 3 (t), total caspase 3; caspase 3 (c), cleaved caspase 3; p, phosphorylated. β-actin and GAPDH, loading controls. Data are representative of three independent experiments. h, Cells were infected with three different short hairpin RNA species targeting NOXA or PUMA before being exposed to bleomycin to induce senescence. Seven days later, cells were treated with PCC1 (100 μM) for a 3-d period to induce apoptosis. SCR, scramble. i, NOXA expression was determined using quantitative PCR with reverse transcription (RT–qPCR). Cells were treated with bleomycin to induce senescence before exposure to 100 μM PCC1 for 3 d in the absence or presence of 10 μM MK2206, 10 μM ruxolitinib or 20 nM BMS-582949 to inhibit the activity of AKT, JAK1 and/or JAK2 or p38 MAPK, respectively. j, A similar set of RT–qPCR expression assays for PUMA using conditions described in i. k–m, Measurement of cell viability after PCC1 treatment in the absence or presence of MK2206 (k), ruxolitinib (l) or BMS-582949 (m), included to inhibit the enzymatic activity of AKT, JAK1 and/or JAK2 or p38 MAPK, respectively. For data in c,d, P values were calculated by one-way ANOVA with Tukey’s post hoc comparison. Statistical significance in h–m was calculated using two-sided t-tests or one-way ANOVA (Dunnett’s test). Data in all bar graphs are shown as mean ± s.d. and represent three biological replicates. NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Source dataCC BY · PubMed Central
Fig. 4 PCC1-induced apoptosis is partially mediated through mitochondrial dysfunction. a, Measurement of ROS levels with DCFH-DA, a cell-permeable fluorescent probe sensitive to changes in cellular redox state. Experiments were performed 1 d after PCC1 treatment. Left, representative images. Scale bar, 10 μm. Right, statistics. DCF, dichlorodihydrofluorescein. b, Immunoblot after exposure of cells to different treatments. Cytochrome c distribution between mitochondria and the cytoplasm was profiled by isolating mitochondria from cytosol supernatants 3 d after PCC1 treatment. COX IV is the terminal enzyme of the mitochondrial respiratory chain and a mitochondrial marker. c, Time course survival curves to assess PSC27 cell viability upon treatment with PCB2, another member of the natural procyanidin family. Data are shown as mean ± s.d. and were derived from three biological replicates (n = 3 independent assays). d, ROS-production assay performed in a similar manner as described in a, except that cells were exposed to PCB2. Scale bar, 10 μm. e, Immunoblot of the expression and distribution of ATM, p53 and caspase 3 between the cytoplasm and the nucleus. GAPDH and lamin A/C, loading controls for cytoplasm and nuclei, respectively. C1, PCC1; B2, PCB2. f, Confocal microscopy of immunofluorescence staining after treatment of cells with vehicle (DMSO) or PCC1. Primary antibodies specific to p53 or COX IV were applied. Scale bar, 10 μm. g, Immunoblot analysis of PSC27 cells exposed to different agents. Cyto, cytoplasmic; mito, mitochondrial. h, Analysis of JC-1 staining, a fluorescent probe indicative of Δψm. Signals were measured over 3 d. Green fluorescence indicates JC-1 monomers (they appear in the cytosol after mitochondrial membrane depolarisation and indicate early-stage apoptosis). Red fluorescence indicates JC-1 aggregation (resides on intact mitochondria). Left, representative images. Right, statistics. Both PCC1 and PCB2 were used at 100 μM in relevant assays. Data in b,e–g are representative of three independent experiments. Statistical significance in a (right), d (right) and h (right) was calculated using two-sided t-tests, and that in c was calculated with one-way ANOVA (Dunnett’s test). Data in all bar graphs are shown as mean ± s.d. and are representative of three biological replicates. NS, P > 0.05; *P < 0.05; **P < 0.01. Source data
Fig. 4 PCC1-induced apoptosis is partially mediated through mitochondrial dysfunction. a, Measurement of ROS levels with DCFH-DA, a cell-permeable fluorescent probe sensitive to changes in cellular redox state. Experiments were performed 1 d after PCC1 treatment. Left, representative images. Scale bar, 10 μm. Right, statistics. DCF, dichlorodihydrofluorescein. b, Immunoblot after exposure of cells to different treatments. Cytochrome c distribution between mitochondria and the cytoplasm was profiled by isolating mitochondria from cytosol supernatants 3 d after PCC1 treatment. COX IV is the terminal enzyme of the mitochondrial respiratory chain and a mitochondrial marker. c, Time course survival curves to assess PSC27 cell viability upon treatment with PCB2, another member of the natural procyanidin family. Data are shown as mean ± s.d. and were derived from three biological replicates (n = 3 independent assays). d, ROS-production assay performed in a similar manner as described in a, except that cells were exposed to PCB2. Scale bar, 10 μm. e, Immunoblot of the expression and distribution of ATM, p53 and caspase 3 between the cytoplasm and the nucleus. GAPDH and lamin A/C, loading controls for cytoplasm and nuclei, respectively. C1, PCC1; B2, PCB2. f, Confocal microscopy of immunofluorescence staining after treatment of cells with vehicle (DMSO) or PCC1. Primary antibodies specific to p53 or COX IV were applied. Scale bar, 10 μm. g, Immunoblot analysis of PSC27 cells exposed to different agents. Cyto, cytoplasmic; mito, mitochondrial. h, Analysis of JC-1 staining, a fluorescent probe indicative of Δψm. Signals were measured over 3 d. Green fluorescence indicates JC-1 monomers (they appear in the cytosol after mitochondrial membrane depolarisation and indicate early-stage apoptosis). Red fluorescence indicates JC-1 aggregation (resides on intact mitochondria). Left, representative images. Right, statistics. Both PCC1 and PCB2 were used at 100 μM in relevant assays. Data in b,e–g are representative of three independent experiments. Statistical significance in a (right), d (right) and h (right) was calculated using two-sided t-tests, and that in c was calculated with one-way ANOVA (Dunnett’s test). Data in all bar graphs are shown as mean ± s.d. and are representative of three biological replicates. NS, P > 0.05; *P < 0.05; **P < 0.01. Source dataCC BY · PubMed Central
Fig. 5 Senolysis by PCC1 in the damaged TME diminishes SASP-conferred cancer resistance. a, Illustrative diagram of a preclinical regimen. Two weeks after subcutaneous implantation and in vivo uptake of tissue recombinants, NOD–SCID male mice received either single (mono) or combined (dual) agents in a metronomic schedule composed of several cycles. BLI, bioluminescence imaging. b, Statistical profiling of tumour end volumes. PC3 cells were xenografted alone or together with PSC27 cells into the hind flank of animals. c, Comparative evaluation of in vivo senescence by SA-β-Gal staining. Tumours were freshly dissected after killing animals and processed as frozen sections for histological staining. Scale bars, 200 μm. d, Violin plots depicting comparative statistics of SA-β-Gal staining in tumour tissues. e, Transcript assay for in vivo expression of several canonical SASP factors in stromal cells isolated from tumours. Tissues from animals xenografted with both stromal and cancer cells were subjected to laser capture microdissection-supported isolation and subsequent processes. Data are representative of three biological replicates (n = 10 animals per group). Datasets are displayed as box-and-whisker plots, in which a box extends from the 25th to the 75th percentile with the median shown as a line in the middle and whiskers indicating smallest and largest values. f, Profiling of SASP transcripts in stromal cells. Signals corresponding to each factor were normalized to those from the vehicle-treated group. Note p16INK4a is also known as CDKN2A and p21CIP1 is also known as CDKN1A. g, Statistical measurement of cells with DNA damage and apoptotic cells in biospecimens collected as described in a,b. Values are presented as the percentage of cells positively stained by immunohistochemistry (IHC) with antibodies specific to histone γH2AX or caspase 3 (cleaved). For b,d–g, P values were calculated by two-sided t-tests. h, Representative IHC images of caspase 3 (cleaved, CC3) at the end of the therapeutic regimes. Scale bars, 100 μm. i, Comparative survival of mice killed after the development of advanced bulky diseases. Survival duration was calculated from the time of recombinant tissue injection until animal death. MS, median survival. P values were calculated by two-sided log-rank (Mantel–Cox) tests. Data in c,h are representative of three independent experiments. Data in all bar graphs are shown as mean ± s.d. and are representative of three biological replicates. Source data
Fig. 5 Senolysis by PCC1 in the damaged TME diminishes SASP-conferred cancer resistance. a, Illustrative diagram of a preclinical regimen. Two weeks after subcutaneous implantation and in vivo uptake of tissue recombinants, NOD–SCID male mice received either single (mono) or combined (dual) agents in a metronomic schedule composed of several cycles. BLI, bioluminescence imaging. b, Statistical profiling of tumour end volumes. PC3 cells were xenografted alone or together with PSC27 cells into the hind flank of animals. c, Comparative evaluation of in vivo senescence by SA-β-Gal staining. Tumours were freshly dissected after killing animals and processed as frozen sections for histological staining. Scale bars, 200 μm. d, Violin plots depicting comparative statistics of SA-β-Gal staining in tumour tissues. e, Transcript assay for in vivo expression of several canonical SASP factors in stromal cells isolated from tumours. Tissues from animals xenografted with both stromal and cancer cells were subjected to laser capture microdissection-supported isolation and subsequent processes. Data are representative of three biological replicates (n = 10 animals per group). Datasets are displayed as box-and-whisker plots, in which a box extends from the 25th to the 75th percentile with the median shown as a line in the middle and whiskers indicating smallest and largest values. f, Profiling of SASP transcripts in stromal cells. Signals corresponding to each factor were normalized to those from the vehicle-treated group. Note p16INK4a is also known as CDKN2A and p21CIP1 is also known as CDKN1A. g, Statistical measurement of cells with DNA damage and apoptotic cells in biospecimens collected as described in a,b. Values are presented as the percentage of cells positively stained by immunohistochemistry (IHC) with antibodies specific to histone γH2AX or caspase 3 (cleaved). For b,d–g, P values were calculated by two-sided t-tests. h, Representative IHC images of caspase 3 (cleaved, CC3) at the end of the therapeutic regimes. Scale bars, 100 μm. i, Comparative survival of mice killed after the development of advanced bulky diseases. Survival duration was calculated from the time of recombinant tissue injection until animal death. MS, median survival. P values were calculated by two-sided log-rank (Mantel–Cox) tests. Data in c,h are representative of three independent experiments. Data in all bar graphs are shown as mean ± s.d. and are representative of three biological replicates. Source dataCC BY · PubMed Central
Fig. 6 PCC1-mediated senolysis prevents physical dysfunction and alleviates pathological symptoms. a, Schematic of experimental procedures for cell transplantation and physical function tests in 5-month-old C57BL/6J male mice. b, Representative images showing in vivo luciferase activity 2 d after the last treatment of mice. Scale bars, 20 mm. c, Luminescence of transplanted cells as a percentage relative to the average signals in vehicle-treated animals. d–f, Measurement of maximal walking speed (relative to baseline) (d), hanging endurance (e) and grip strength (f) in 5-month-old C57BL/6J male mice, with tests performed 1 month after the last treatment. g, Schematic of the experimental design for transplantation and physical function measurements. h–j, Measurement of maximal walking speed (relative to baseline) (h), hanging endurance (i) and grip strength (j) in 28-week-old C57BL/6J male mice (2 weeks after the last treatment). k, One-year survival curves of 17-month-old animals implanted with 0.5 × 106 control MEF cells and treated with vehicle (CTRL-vehicle) and mice implanted with 0.5 × 106 senescent MEF cells treated either with vehicle (SEN-vehicle) or PCC1 (SEN-PCC1). Red arrowheads, cell implantation (on the 528th day of age) or the end of survival measurement (890th day of age). P values were calculated by two-sided log-rank (Mantel–Cox) tests. l, Comparative quantification of disease burden (left) and tumour burden (right) (shown as median with interquartile range) after implantation of senescent cells and treatment with vehicle or PCC1. m, Cause of death in animals that received implanted cells and were treated with vehicle or PCC1. For d–f,h–j, data are shown as box-and-whisker plots, in which boxes extend from the 25th to the 75th percentile with the median shown as a line in the middle, and whiskers indicate smallest and largest values. For c–f,h–j, P values were calculated by two-sided t-tests. Number of animals, n = 5 per group for c, n = 10 per group for d–j, n = 27 for k and n = 13 for l,m. NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Source data
Fig. 6 PCC1-mediated senolysis prevents physical dysfunction and alleviates pathological symptoms. a, Schematic of experimental procedures for cell transplantation and physical function tests in 5-month-old C57BL/6J male mice. b, Representative images showing in vivo luciferase activity 2 d after the last treatment of mice. Scale bars, 20 mm. c, Luminescence of transplanted cells as a percentage relative to the average signals in vehicle-treated animals. d–f, Measurement of maximal walking speed (relative to baseline) (d), hanging endurance (e) and grip strength (f) in 5-month-old C57BL/6J male mice, with tests performed 1 month after the last treatment. g, Schematic of the experimental design for transplantation and physical function measurements. h–j, Measurement of maximal walking speed (relative to baseline) (h), hanging endurance (i) and grip strength (j) in 28-week-old C57BL/6J male mice (2 weeks after the last treatment). k, One-year survival curves of 17-month-old animals implanted with 0.5 × 106 control MEF cells and treated with vehicle (CTRL-vehicle) and mice implanted with 0.5 × 106 senescent MEF cells treated either with vehicle (SEN-vehicle) or PCC1 (SEN-PCC1). Red arrowheads, cell implantation (on the 528th day of age) or the end of survival measurement (890th day of age). P values were calculated by two-sided log-rank (Mantel–Cox) tests. l, Comparative quantification of disease burden (left) and tumour burden (right) (shown as median with interquartile range) after implantation of senescent cells and treatment with vehicle or PCC1. m, Cause of death in animals that received implanted cells and were treated with vehicle or PCC1. For d–f,h–j, data are shown as box-and-whisker plots, in which boxes extend from the 25th to the 75th percentile with the median shown as a line in the middle, and whiskers indicate smallest and largest values. For c–f,h–j, P values were calculated by two-sided t-tests. Number of animals, n = 5 per group for c, n = 10 per group for d–j, n = 27 for k and n = 13 for l,m. NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Source dataCC BY · PubMed Central
Fig. 7 PCC1 treatment alleviates physical dysfunction of animals exposed to WBI. a, Schematic of the experimental procedure for mice experiencing WBI and physical function tests. b, Whole-body snapshot comparison of C57BL/6J male mice that were naive, exposed to WBI followed by vehicle treatment or exposed to WBI and treated with PCC1, respectively. c, An in-cage picture of animals described in a under preclinical conditions. d, Representative images of SA-β-Gal staining of cardiac tissue of untreated (naive) and WBI-treated mice subjected to vehicle or PCC1 treatment. Scale bar, 200 μm. e, Representative images of SA-β-Gal staining of pulmonary tissue of mice as described in d. Scale bar, 200 μm. f, Comparative statistics of SA-β-Gal staining of cardiac tissue of animals examined in d. g, Comparative statistics of SA-β-Gal staining of pulmonary tissue of animals examined in e. h, Quantitative measurement of SASP expression at the transcription level in tissues collected from animals treated under conditions described in a. i,j, Measurement of running distance on the treadmill (i) and grip strength (j) of experimental mice. For f–j, P values were calculated by two-sided t-tests. k, Kaplan–Meier survival analysis of C57BL/6J mice exposed to WBI and treated weekly with vehicle or PCC1, with naive mice as the untreated control. CI, confidence interval; HR, hazard ratio; DFI, disease-free interval. P values were calculated by two-sided log-rank (Mantel–Cox) tests. Data in bar graphs are shown as mean ± s.d. and are representative of three independent experiments. NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Source data
Fig. 7 PCC1 treatment alleviates physical dysfunction of animals exposed to WBI. a, Schematic of the experimental procedure for mice experiencing WBI and physical function tests. b, Whole-body snapshot comparison of C57BL/6J male mice that were naive, exposed to WBI followed by vehicle treatment or exposed to WBI and treated with PCC1, respectively. c, An in-cage picture of animals described in a under preclinical conditions. d, Representative images of SA-β-Gal staining of cardiac tissue of untreated (naive) and WBI-treated mice subjected to vehicle or PCC1 treatment. Scale bar, 200 μm. e, Representative images of SA-β-Gal staining of pulmonary tissue of mice as described in d. Scale bar, 200 μm. f, Comparative statistics of SA-β-Gal staining of cardiac tissue of animals examined in d. g, Comparative statistics of SA-β-Gal staining of pulmonary tissue of animals examined in e. h, Quantitative measurement of SASP expression at the transcription level in tissues collected from animals treated under conditions described in a. i,j, Measurement of running distance on the treadmill (i) and grip strength (j) of experimental mice. For f–j, P values were calculated by two-sided t-tests. k, Kaplan–Meier survival analysis of C57BL/6J mice exposed to WBI and treated weekly with vehicle or PCC1, with naive mice as the untreated control. CI, confidence interval; HR, hazard ratio; DFI, disease-free interval. P values were calculated by two-sided log-rank (Mantel–Cox) tests. Data in bar graphs are shown as mean ± s.d. and are representative of three independent experiments. NS, P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Source dataCC BY · PubMed Central
Fig. 8 Intermittent PCC1 administration extends both healthspan and lifespan of aged mice. a, Schematic design for physical examination of 20-month-old C57BL/6J male mice treated with PCC1 once every 2 weeks (biweekly) for 4 months. b, Representative images of SA-β-Gal staining of kidneys from young and aged mice treated with vehicle or PCC1. Scale bar, 200 μm. c, Quantification of SA-β-Gal staining as described in b. Data represent mean ± s.d. d–h, Quantification of maximal walking speed (relative to baseline) (d), hanging endurance (e), grip strength (f), treadmill endurance (g) and daily activity (h) of 20-month-old C57BL/6J male mice after the 4-month treatment. i, Quantification of the time needed to cross the balance beam. Data points before and after treatment of each animal are connected to allow direct comparison of treatment effects. j, Quantitative transcript profiling of SASP expression in lung tissues collected from 6-month-old untreated (6M), 24-month-old vehicle-treated (24M-vehicle) and 24-month-old PCC1-treated mice (24M-PCC1). Data are shown as mean ± s.d. and were derived from three biological replicates (n = 3 independent assays). k, Schematic design for lifespan analyses of mice (both sexes) at 24–27 months of age. l,m, Post-treatment survival (l) and whole-life survival (m) curves of C57BL/6J animals treated biweekly with PCC1 (n = 91; 48 males, 43 females) or vehicle (n = 80; 42 males, 38 females) starting at 24–27 months of age. n, Maximal walking speed and hanging endurance averaged over the last 2 months of life (n = 10 mice per group) and lifespan for the longest-living mice (top 20) in both groups. o, Disease burden and tumour burden at death. For both sexes, n = 60 mice per arm. For males, n = 31 for PCC1 and n = 33 for vehicle. For females, n = 29 for PCC1 and n = 27 for vehicle. For c–h,j, n = 3 biologically independent assays. Data are displayed as box-and-whisker plots, in which a box extends from the 25th to the 75th percentile with the median shown as a line in the middle, and whiskers indicate smallest and largest values (d–h,n) or as mean ± s.d. (o). Unpaired two-tailed t-tests (c–j,n,o) and Cox proportional-hazard regression models (l,m) were used to determine statistical significance. Source data
Fig. 8 Intermittent PCC1 administration extends both healthspan and lifespan of aged mice. a, Schematic design for physical examination of 20-month-old C57BL/6J male mice treated with PCC1 once every 2 weeks (biweekly) for 4 months. b, Representative images of SA-β-Gal staining of kidneys from young and aged mice treated with vehicle or PCC1. Scale bar, 200 μm. c, Quantification of SA-β-Gal staining as described in b. Data represent mean ± s.d. d–h, Quantification of maximal walking speed (relative to baseline) (d), hanging endurance (e), grip strength (f), treadmill endurance (g) and daily activity (h) of 20-month-old C57BL/6J male mice after the 4-month treatment. i, Quantification of the time needed to cross the balance beam. Data points before and after treatment of each animal are connected to allow direct comparison of treatment effects. j, Quantitative transcript profiling of SASP expression in lung tissues collected from 6-month-old untreated (6M), 24-month-old vehicle-treated (24M-vehicle) and 24-month-old PCC1-treated mice (24M-PCC1). Data are shown as mean ± s.d. and were derived from three biological replicates (n = 3 independent assays). k, Schematic design for lifespan analyses of mice (both sexes) at 24–27 months of age. l,m, Post-treatment survival (l) and whole-life survival (m) curves of C57BL/6J animals treated biweekly with PCC1 (n = 91; 48 males, 43 females) or vehicle (n = 80; 42 males, 38 females) starting at 24–27 months of age. n, Maximal walking speed and hanging endurance averaged over the last 2 months of life (n = 10 mice per group) and lifespan for the longest-living mice (top 20) in both groups. o, Disease burden and tumour burden at death. For both sexes, n = 60 mice per arm. For males, n = 31 for PCC1 and n = 33 for vehicle. For females, n = 29 for PCC1 and n = 27 for vehicle. For c–h,j, n = 3 biologically independent assays. Data are displayed as box-and-whisker plots, in which a box extends from the 25th to the 75th percentile with the median shown as a line in the middle, and whiskers indicate smallest and largest values (d–h,n) or as mean ± s.d. (o). Unpaired two-tailed t-tests (c–j,n,o) and Cox proportional-hazard regression models (l,m) were used to determine statistical significance. Source dataCC BY · PubMed Central
Extended Data Fig. 1 In vitro screening of a natural product library with human stromal cells. (a) Schematic workflow of cell-based screening strategy for a natural library of medicinal agents. (b) Quantification of cell survival of control (CTRL) and senescent (SEN) PSC27 after treatment with ABT-263 (1.25 μM), ABT-737 (10 μM) or Dasatinib (250 nM) combined with Quercetin (50 μM) for 3 d. (c) Screening results after pharmacological assays. Library agents were assessed at a concentration of 3 μg/ml with 5.0 × 103 cells for 3 d. Hits were selected based on their ability to specifically kill senescent cells. Each blue dot represents a single agent as the mean of three replicates. Red rectangular region denotes potential candidates of senolytics in the case of TIS. (d) Appraisal of the effects of randomly selected agents (23 representative candidates out of 46 in the library, each applied at 1 μg/ml) on the survival of CTRL and SEN cells. (e) Assessment of the effects of remaining agents (23 candidates out of 46 in the library, each applied at 1 μg/ml) on the survival of CTRL and SEN cells. For all datasets, samples were collected for analyses 3 days after treatment with individual agents in culture condition. TIS, therapy-induced senescence. Data in b, d and e are shown as mean ± SD and representative of 3 independent biological replicates, with P values calculated by a two-sided t-test. *, P < 0.05; **, P < 0.01. Source data
Extended Data Fig. 1 In vitro screening of a natural product library with human stromal cells. (a) Schematic workflow of cell-based screening strategy for a natural library of medicinal agents. (b) Quantification of cell survival of control (CTRL) and senescent (SEN) PSC27 after treatment with ABT-263 (1.25 μM), ABT-737 (10 μM) or Dasatinib (250 nM) combined with Quercetin (50 μM) for 3 d. (c) Screening results after pharmacological assays. Library agents were assessed at a concentration of 3 μg/ml with 5.0 × 103 cells for 3 d. Hits were selected based on their ability to specifically kill senescent cells. Each blue dot represents a single agent as the mean of three replicates. Red rectangular region denotes potential candidates of senolytics in the case of TIS. (d) Appraisal of the effects of randomly selected agents (23 representative candidates out of 46 in the library, each applied at 1 μg/ml) on the survival of CTRL and SEN cells. (e) Assessment of the effects of remaining agents (23 candidates out of 46 in the library, each applied at 1 μg/ml) on the survival of CTRL and SEN cells. For all datasets, samples were collected for analyses 3 days after treatment with individual agents in culture condition. TIS, therapy-induced senescence. Data in b, d and e are shown as mean ± SD and representative of 3 independent biological replicates, with P values calculated by a two-sided t-test. *, P < 0.05; **, P < 0.01. Source dataCC BY · PubMed Central
Extended Data Fig. 2 Bioinformatics profiling of the effect of GSE on genome-wide expression of senescent cells. (a) Quantitative analysis of SASP factor expression at transcription level upon treatment of BLEO-induced senescent cells with different concentrations of GSE in culture. P values were calculated by one-way ANOVA with Tukey’s multiple-comparison test. (b) Heatmap depicting the expression landscape of senescent cells and their counterparts exposed to GSE (0.1875 μg/ml). Note there were 2644 and 1472 genes, expression of which was significantly downregulated and upregulated by GSE, respectively. (c) Heatmap depicting the expression profiles of human genes in CTRL cells, SEN cells or SEN cells treated by GSE. According to the fold change of transcript expression, the top 50 genes are displayed. (d) GSEA plot of significant gene set indicative of a typical SASP. (e) GSEA plot of significant gene set associated with the activation of NF-κB signaling. For d and e, P values were calculated by one-way ANOVA with Tukey’s post hoc comparison. (f) Immunoblot analysis of DNA damage repair signaling, p65 nuclear translocation and CXCL8 expression in PSC27 cells (CTRL or SEN) exposed to GSE treatment. L, a representative low concentration (0.1875 μg/ml). H, a representative high concentration (3.7500 μg/ml). Cellular senescence was induced by the genotoxic chemical bleomycin (BLEO), which causes a typical TIS. For all datasets, cells were collected for analyses 3 days after GSE treatment in culture condition. Data in a and f are representative of 3 independent biological replicates. Source data
Extended Data Fig. 2 Bioinformatics profiling of the effect of GSE on genome-wide expression of senescent cells. (a) Quantitative analysis of SASP factor expression at transcription level upon treatment of BLEO-induced senescent cells with different concentrations of GSE in culture. P values were calculated by one-way ANOVA with Tukey’s multiple-comparison test. (b) Heatmap depicting the expression landscape of senescent cells and their counterparts exposed to GSE (0.1875 μg/ml). Note there were 2644 and 1472 genes, expression of which was significantly downregulated and upregulated by GSE, respectively. (c) Heatmap depicting the expression profiles of human genes in CTRL cells, SEN cells or SEN cells treated by GSE. According to the fold change of transcript expression, the top 50 genes are displayed. (d) GSEA plot of significant gene set indicative of a typical SASP. (e) GSEA plot of significant gene set associated with the activation of NF-κB signaling. For d and e, P values were calculated by one-way ANOVA with Tukey’s post hoc comparison. (f) Immunoblot analysis of DNA damage repair signaling, p65 nuclear translocation and CXCL8 expression in PSC27 cells (CTRL or SEN) exposed to GSE treatment. L, a representative low concentration (0.1875 μg/ml). H, a representative high concentration (3.7500 μg/ml). Cellular senescence was induced by the genotoxic chemical bleomycin (BLEO), which causes a typical TIS. For all datasets, cells were collected for analyses 3 days after GSE treatment in culture condition. Data in a and f are representative of 3 independent biological replicates. Source dataCC BY · PubMed Central
Extended Data Fig. 3 Bioinformatics profiling of the effect of GSE on the intracellular signaling network of senescent cells. (a) Mapping of protein-protein interaction (PPI) for BLEO-upregulated but GSE-downregulated genes by STRING program. (b-c) Column charts depicting the biological processes (BP) (b) and cellular components (CC) (c) pronouncedly associated with transcripts upregulated by BLEO but downregulated by GSE as revealed by GO analysis.
Extended Data Fig. 3 Bioinformatics profiling of the effect of GSE on the intracellular signaling network of senescent cells. (a) Mapping of protein-protein interaction (PPI) for BLEO-upregulated but GSE-downregulated genes by STRING program. (b-c) Column charts depicting the biological processes (BP) (b) and cellular components (CC) (c) pronouncedly associated with transcripts upregulated by BLEO but downregulated by GSE as revealed by GO analysis.CC BY · PubMed Central
Extended Data Fig. 4 In vitro cell assays identify PCC1 as a broad-spectrum senolytic. (a) Representative images displaying SA-β-Gal staining results after treatment of PSC27 cells with increasing concentrations of PCC1. Scale bar, 30 μm. Data are representative of 3 independent experiments. (b) Senolytic activity appraisal by measuring the percentage of surviving senescent PSC27 cells induced by replicative exhaustion (RS) at increasing PCC1 concentrations. (c) Caspase 3/7 activity-based apoptotic evaluation of CTRL and RS cells treated by PCC1. (d) Senolytic activity assessment by determining the percentage of surviving senescent cells induced by oncogenic HRasG12V (OIS) at increasing PCC1 concentrations. For b and d, P values were calculated by two-sided t-test. (e) Caspase 3/7 activity-based apoptotic appraisal of CTRL and OIS cells treated by PCC1. (f-h) Quantification of the viability of cells in CTRL, TIS, RS and OIS groups treated by 100 μM PCC1 for 3 d. (f), WI38. (g), HUVEC. (h), MSC. The significance of P values for the first concentration of PCC1 that differentiating the survival of CTRL and SEN cells was marked per cell line-based assay. For f, g and h, P values were calculated by one-way ANOVA with Tukey’s multiple-comparison test. (i) Quantification of cell survival in CTRL and SEN populations after combined treatment of 100 μM PCC1 with a ferroptosis inhibitor (liproxstatin-1), necroptosis inhibitor (Nec-1s), caspase-1 inhibitor (VX-765), or a pan-caspase inhibitor (QVD-O-Ph). Cell survival was presented as comparative data of different concentrations of chemicals relative to cells treated by the vehicle. P values were calculated by two-sided t-test. All data are shown as mean ± SD, and are representative of 3 biological replicates. ^, P > 0.05. *, P < 0.05. **, P < 0.01. ***, P < 0.001. ****, P < 0.0001. Source data
Extended Data Fig. 4 In vitro cell assays identify PCC1 as a broad-spectrum senolytic. (a) Representative images displaying SA-β-Gal staining results after treatment of PSC27 cells with increasing concentrations of PCC1. Scale bar, 30 μm. Data are representative of 3 independent experiments. (b) Senolytic activity appraisal by measuring the percentage of surviving senescent PSC27 cells induced by replicative exhaustion (RS) at increasing PCC1 concentrations. (c) Caspase 3/7 activity-based apoptotic evaluation of CTRL and RS cells treated by PCC1. (d) Senolytic activity assessment by determining the percentage of surviving senescent cells induced by oncogenic HRasG12V (OIS) at increasing PCC1 concentrations. For b and d, P values were calculated by two-sided t-test. (e) Caspase 3/7 activity-based apoptotic appraisal of CTRL and OIS cells treated by PCC1. (f-h) Quantification of the viability of cells in CTRL, TIS, RS and OIS groups treated by 100 μM PCC1 for 3 d. (f), WI38. (g), HUVEC. (h), MSC. The significance of P values for the first concentration of PCC1 that differentiating the survival of CTRL and SEN cells was marked per cell line-based assay. For f, g and h, P values were calculated by one-way ANOVA with Tukey’s multiple-comparison test. (i) Quantification of cell survival in CTRL and SEN populations after combined treatment of 100 μM PCC1 with a ferroptosis inhibitor (liproxstatin-1), necroptosis inhibitor (Nec-1s), caspase-1 inhibitor (VX-765), or a pan-caspase inhibitor (QVD-O-Ph). Cell survival was presented as comparative data of different concentrations of chemicals relative to cells treated by the vehicle. P values were calculated by two-sided t-test. All data are shown as mean ± SD, and are representative of 3 biological replicates. ^, P > 0.05. *, P < 0.05. **, P < 0.01. ***, P < 0.001. ****, P < 0.0001. Source dataCC BY · PubMed Central
Extended Data Fig. 5 Characterization of PCC1-induced apoptosis of senescent cells. (a) Survival assays of PSC27 cells infected with lentivirus encoding shRNAs against indicated factors. Cells were exposed to PCC1 (100 μM) 7 days after BLEO-caused senescence, for a 3-d period to induce apoptosis. SCR, scramble. P values were calculated by one-way ANOVA with Tukey’s multiple-comparison test. (b) Immunoblot profiling Noxa expression in PSC27 cells infected with lentivirus encoding shRNAs specific for Noxa before treatment with different agents. (c) Immunoblot profiling Puma expression in PSC27 cells, in a workflow resembling that of Noxa. (d) Staining of ROS in senescent PSC27 cells with 2’-7’-dichlorodihydrofluorescein diacetate (DCFH-DA), a cell permeable fluorescent probe indicative of changes in redox state. Signals were measured in a 4-d time course starting from PCC treatment. Scale bar, 20 μm. (e) Examination of ROS by DCFH-DA-staining. Cells were exposed to different agents 7 days after BLEO challenge, for a 3-day period. Staining with DCFH-DA was performed 1 day after addition of individual agents. Scale bar, 20 μm. (f) Statistical comparison of ROS signal intensity measured for cells described in (e). (g) Apoptotic assay of PSC27 cells exposed to in vitro treatments described in (e) by examination of caspase 3/7 activity. Signals from DMSO treatment as a baseline, with indicated P values derived from comparison against PCC1-treated samples. Data are shown as mean ± SD and derive from 3 biological replicates (n = 3 independent assays). P values were calculated by two-sided t-test. (h) Immunoblot of cytochrome c in cells exposed to PCC1. (i) Immunoblot of cytochrome c in cells exposed to PCB2. For (h) and (i), distribution of cytochrome c between mitochondria and cytoplasm was profiled by isolating mitochondria from cytosol supernatants at specialized timepoints (day 0-3 for h, and 3 for i) after procyanidin treatment. COX IV, mitochondrial marker. Data of b-d, h-i are representative of 3 independent experiments. Data of bar graphs (a and f) are shown as mean ± SD and represent 3 biological replicates. ^, P > 0.05. *, P < 0.05. **, P < 0.01. ***, P < 0.001. ****, P < 0.0001. Source data
Extended Data Fig. 5 Characterization of PCC1-induced apoptosis of senescent cells. (a) Survival assays of PSC27 cells infected with lentivirus encoding shRNAs against indicated factors. Cells were exposed to PCC1 (100 μM) 7 days after BLEO-caused senescence, for a 3-d period to induce apoptosis. SCR, scramble. P values were calculated by one-way ANOVA with Tukey’s multiple-comparison test. (b) Immunoblot profiling Noxa expression in PSC27 cells infected with lentivirus encoding shRNAs specific for Noxa before treatment with different agents. (c) Immunoblot profiling Puma expression in PSC27 cells, in a workflow resembling that of Noxa. (d) Staining of ROS in senescent PSC27 cells with 2’-7’-dichlorodihydrofluorescein diacetate (DCFH-DA), a cell permeable fluorescent probe indicative of changes in redox state. Signals were measured in a 4-d time course starting from PCC treatment. Scale bar, 20 μm. (e) Examination of ROS by DCFH-DA-staining. Cells were exposed to different agents 7 days after BLEO challenge, for a 3-day period. Staining with DCFH-DA was performed 1 day after addition of individual agents. Scale bar, 20 μm. (f) Statistical comparison of ROS signal intensity measured for cells described in (e). (g) Apoptotic assay of PSC27 cells exposed to in vitro treatments described in (e) by examination of caspase 3/7 activity. Signals from DMSO treatment as a baseline, with indicated P values derived from comparison against PCC1-treated samples. Data are shown as mean ± SD and derive from 3 biological replicates (n = 3 independent assays). P values were calculated by two-sided t-test. (h) Immunoblot of cytochrome c in cells exposed to PCC1. (i) Immunoblot of cytochrome c in cells exposed to PCB2. For (h) and (i), distribution of cytochrome c between mitochondria and cytoplasm was profiled by isolating mitochondria from cytosol supernatants at specialized timepoints (day 0-3 for h, and 3 for i) after procyanidin treatment. COX IV, mitochondrial marker. Data of b-d, h-i are representative of 3 independent experiments. Data of bar graphs (a and f) are shown as mean ± SD and represent 3 biological replicates. ^, P > 0.05. *, P < 0.05. **, P < 0.01. ***, P < 0.001. ****, P < 0.0001. Source dataCC BY · PubMed Central
Extended Data Fig. 6 Schematic design of preclinical trial, expression analysis of the SASP and pathophysiological appraisal of treatments. (a) Statistics of tumor end volumes. PC3 cells were xenografted alone or together with PSC27 to the hind flank of animals, with tumor volumes measured at the end of an 8-week period. (b) Cancer cells (PC3) alone or alongside stromal cells (PSC27) were inoculated subcutaneously to NOD/SCID males 2 weeks before chemotherapy. MIT was delivered via intravenous injection on the 1st day of each week starting from the 3rd week, then given every other week, totally 3 doses. PCC1 administered via i.p. starting from beginning of the 5th week, then once per 2 weeks. At the end of 8 weeks mice were sacrificed, tumor volume measured and tissues assessed. (c) Transcript analysis of canonical SASP factors (GM-CSF/MMP3/IL1α) and p16INK4a expressed in epithelial and stromal cells, respectively. Individual cell types isolated from tumor tissues via LCM. Data are representative of 3 biological replicates (n = 10 animals per group). Datasets are displayed as box-and-whisker plots, where a box extends from the 25th to 75th percentile with the median shown as a line in the middle, with whiskers indicating smallest and largest values. P values were calculated by two-sided t-test. (d) Heatmap depicting top genes (50) significantly upregulated in PSC27 xenografted subcutaneously to mice and induced senescent by MIT. Gene expression in animals experiencing MIT/PCC1 co-treatment also profiled, with transcript signals normalized to vehicle-treated group. Red stars, SASP factors. (e) Body weight determination performed on a weekly basis for immunodeficient mice. (f) Serum measurement of creatinine, urea, alkaline phosphatase (ALP), and alanine aminotransferase (ALT) with terminal bleeds (cardiac punctures) taken at the end of therapeutic regimens. For a and c, P values were calculated by two-sided t-test. For e-f, P values were calculated by one-way ANOVA with Tukey’s multiple-comparison test. Data in a, e and f are shown as mean ± SD and representative of 3 independent experiments. MIT, mitoxantrone. For each dataset, n = 10 per treatment arm. Source data
Extended Data Fig. 6 Schematic design of preclinical trial, expression analysis of the SASP and pathophysiological appraisal of treatments. (a) Statistics of tumor end volumes. PC3 cells were xenografted alone or together with PSC27 to the hind flank of animals, with tumor volumes measured at the end of an 8-week period. (b) Cancer cells (PC3) alone or alongside stromal cells (PSC27) were inoculated subcutaneously to NOD/SCID males 2 weeks before chemotherapy. MIT was delivered via intravenous injection on the 1st day of each week starting from the 3rd week, then given every other week, totally 3 doses. PCC1 administered via i.p. starting from beginning of the 5th week, then once per 2 weeks. At the end of 8 weeks mice were sacrificed, tumor volume measured and tissues assessed. (c) Transcript analysis of canonical SASP factors (GM-CSF/MMP3/IL1α) and p16INK4a expressed in epithelial and stromal cells, respectively. Individual cell types isolated from tumor tissues via LCM. Data are representative of 3 biological replicates (n = 10 animals per group). Datasets are displayed as box-and-whisker plots, where a box extends from the 25th to 75th percentile with the median shown as a line in the middle, with whiskers indicating smallest and largest values. P values were calculated by two-sided t-test. (d) Heatmap depicting top genes (50) significantly upregulated in PSC27 xenografted subcutaneously to mice and induced senescent by MIT. Gene expression in animals experiencing MIT/PCC1 co-treatment also profiled, with transcript signals normalized to vehicle-treated group. Red stars, SASP factors. (e) Body weight determination performed on a weekly basis for immunodeficient mice. (f) Serum measurement of creatinine, urea, alkaline phosphatase (ALP), and alanine aminotransferase (ALT) with terminal bleeds (cardiac punctures) taken at the end of therapeutic regimens. For a and c, P values were calculated by two-sided t-test. For e-f, P values were calculated by one-way ANOVA with Tukey’s multiple-comparison test. Data in a, e and f are shown as mean ± SD and representative of 3 independent experiments. MIT, mitoxantrone. For each dataset, n = 10 per treatment arm. Source dataCC BY · PubMed Central
Extended Data Fig. 7 PCC1 alleviates physical dysfunction of animals transplanted with senescent cells. (a) Maximal walking speed (relative to the baseline) of 5-month-old C57BL/6 J males at different time points post transplantation of 1 ×106 SEN stromal cells and treatment with PCC1 or vehicle (V). (b) Hanging endurance (measured as sec x g) of 5-month-old C57BL/6 J males at different time points as described in (a). Data are representative of 3 biological replicates (n = 10 animals per group). Datasets are displayed as box-and-whisker plots, where a box extends from the 25th to 75th percentile with the median shown as a line in the middle, with whiskers indicating smallest and largest values. For a-b, P values were calculated by two-sided t-test. ^, P > 0.05. *, P < 0.05. **, P < 0.01. ***, P < 0.001. Source data
Extended Data Fig. 7 PCC1 alleviates physical dysfunction of animals transplanted with senescent cells. (a) Maximal walking speed (relative to the baseline) of 5-month-old C57BL/6 J males at different time points post transplantation of 1 ×106 SEN stromal cells and treatment with PCC1 or vehicle (V). (b) Hanging endurance (measured as sec x g) of 5-month-old C57BL/6 J males at different time points as described in (a). Data are representative of 3 biological replicates (n = 10 animals per group). Datasets are displayed as box-and-whisker plots, where a box extends from the 25th to 75th percentile with the median shown as a line in the middle, with whiskers indicating smallest and largest values. For a-b, P values were calculated by two-sided t-test. ^, P > 0.05. *, P < 0.05. **, P < 0.01. ***, P < 0.001. Source dataCC BY · PubMed Central
Extended Data Fig. 8 Intermittent administration of PCC1 alleviates physical dysfunction of aged mice. (a) Representative images of SA-β-Gal staining of liver tissues from young (6 months of age) and aged males treated with vehicle or PCC1. Scale bar, 200 μm. (b) Comparative statistics of SA-β-Gal staining positivity of samples assayed in (a). (c) Representative images of SA-β-Gal staining of lung tissues from young and aged mice treated with vehicle or PCC1. Scale bar, 200 μm. (d) Comparative statistics of SA-β-Gal staining positivity of samples examined in (c). (e) Representative images of SA-β-Gal staining of prostate tissues from young and aged mice treated with vehicle or PCC1. Scale bar, 200 μm. (f) Comparative statistics of SA-β-Gal staining positivity of samples examined in (e). (g) Quantification of body weight of animals as described in (a). (h) Measurement of food intake of animals as described in (a). Data in g and h are representative of 3 biological replicates (n = 10 animals per group). Datasets are displayed as box-and-whisker plots, where a box extends from the 25th to 75th percentile with the median shown as a line in the middle, with whiskers indicating smallest and largest values. Data in bar graphs (b, d and f) are shown as mean ± SD (n = 5 animals per group) and representative of 3 independent experiments. For b, d, f, g and h, P values were calculated by two-sided t-test. ^, P > 0.05. *, P < 0.05. **, P < 0.01. ***, P < 0.001. Source data
Extended Data Fig. 8 Intermittent administration of PCC1 alleviates physical dysfunction of aged mice. (a) Representative images of SA-β-Gal staining of liver tissues from young (6 months of age) and aged males treated with vehicle or PCC1. Scale bar, 200 μm. (b) Comparative statistics of SA-β-Gal staining positivity of samples assayed in (a). (c) Representative images of SA-β-Gal staining of lung tissues from young and aged mice treated with vehicle or PCC1. Scale bar, 200 μm. (d) Comparative statistics of SA-β-Gal staining positivity of samples examined in (c). (e) Representative images of SA-β-Gal staining of prostate tissues from young and aged mice treated with vehicle or PCC1. Scale bar, 200 μm. (f) Comparative statistics of SA-β-Gal staining positivity of samples examined in (e). (g) Quantification of body weight of animals as described in (a). (h) Measurement of food intake of animals as described in (a). Data in g and h are representative of 3 biological replicates (n = 10 animals per group). Datasets are displayed as box-and-whisker plots, where a box extends from the 25th to 75th percentile with the median shown as a line in the middle, with whiskers indicating smallest and largest values. Data in bar graphs (b, d and f) are shown as mean ± SD (n = 5 animals per group) and representative of 3 independent experiments. For b, d, f, g and h, P values were calculated by two-sided t-test. ^, P > 0.05. *, P < 0.05. **, P < 0.01. ***, P < 0.001. Source dataCC BY · PubMed Central
Extended Data Fig. 9 Late life intervention with PCC1 does not alter the cause of death, but restrains the SASP and reduces oxidative stress. (a-b) Pie charts depicting the ultimate causes of death of C57BL/6 J mice (males and females) that had undergone vehicle (a) or PCC1 (b) biweekly treatment starting from 24-27 months of age. Note there was no significant difference between vehicle- and PCC1-treated groups upon analysis using either Chi-square or Fisher’s exact tests. (c-e) qRT-PCR profiling of the SASP and senescence marker expression in tissues of solid organs, including liver (c), lung (d) and prostate (e) collected from young (6-month-old, untreated), aged (24-27-month-old) vehicle-treated and aged (24-27-month-old) PCC1-treated animals, respectively. (f) Measurement of circulating levels of hallmark SASP factors IL6, CSF2 and MCP-1 in mouse blood by ELISA assays. (g) Quantification of SASP and senescence marker expression in CD3+ peripheral T cells of experimental mice described in c-f. (h) Examination of 4-hydroxynonenal (HNE) adducts, a marker of lipid peroxidation and oxidative stress by ELISA measurement with tissue lysates of the liver. (i) Determination of the ratio of reduced (GSH) to oxidized (GSSG) glutathione measured as an index oxidative stress. Data are shown as mean ± SD and derive from 3 biological replicates (n = 3 independent assays for c-i). P values were calculated by two-sided t-test. ^, P > 0.05. *, P < 0.05. **, P < 0.01. ***, P < 0.001. Source data
Extended Data Fig. 9 Late life intervention with PCC1 does not alter the cause of death, but restrains the SASP and reduces oxidative stress. (a-b) Pie charts depicting the ultimate causes of death of C57BL/6 J mice (males and females) that had undergone vehicle (a) or PCC1 (b) biweekly treatment starting from 24-27 months of age. Note there was no significant difference between vehicle- and PCC1-treated groups upon analysis using either Chi-square or Fisher’s exact tests. (c-e) qRT-PCR profiling of the SASP and senescence marker expression in tissues of solid organs, including liver (c), lung (d) and prostate (e) collected from young (6-month-old, untreated), aged (24-27-month-old) vehicle-treated and aged (24-27-month-old) PCC1-treated animals, respectively. (f) Measurement of circulating levels of hallmark SASP factors IL6, CSF2 and MCP-1 in mouse blood by ELISA assays. (g) Quantification of SASP and senescence marker expression in CD3+ peripheral T cells of experimental mice described in c-f. (h) Examination of 4-hydroxynonenal (HNE) adducts, a marker of lipid peroxidation and oxidative stress by ELISA measurement with tissue lysates of the liver. (i) Determination of the ratio of reduced (GSH) to oxidized (GSSG) glutathione measured as an index oxidative stress. Data are shown as mean ± SD and derive from 3 biological replicates (n = 3 independent assays for c-i). P values were calculated by two-sided t-test. ^, P > 0.05. *, P < 0.05. **, P < 0.01. ***, P < 0.001. Source dataCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 77 references

Cited by

See all 341

Metadata

Authors
Xu, Q., Fu, Q., Li, Z., Liu, H., Wang, Y., Lin, X., He, R., Zhang, X., Ju, Z., Campisi, J., Kirkland, J. L., & Sun, Y.
Affiliations
  • Shanghai Jiao Tong University (CN)
  • Binzhou Medical University (CN)
  • Chinese Academy of Sciences (CN)
  • Shanghai Institute of Nutrition and Health (CN)
  • Jinan University (CN)
  • Buck Institute for Research on Aging (US)
  • Mayo Clinic (US)
Corresponding author
Sun, Yu
Venue
Nature Metabolism
Published
2021-12-06
Volume
3
Issue
12
Pages
1706-1726
ISSN
2522-5812 (ISSN-L)
OpenAlex
W4200000184
Cited by
341
References
77
Citations by year
2026: 66 · 2025: 103 · 2024: 73 · 2023: 54 · 2022: 43 · 2021: 2
FWCI
26.98
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Metabolism (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
National Natural Science Foundation of China (81472709, 31671425, 31871380, 82130045)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
procyanidin C1, grape seed extract, senolytics, senescence-associated secretory phenotype, senescent cells, lifespan extension, healthspan, aging, reactive oxygen species, mitochondrial dysfunction, tumor microenvironment, combination chemotherapy, flavonoids, natural products
MeSH terms
Drug Development, Senescence-Associated Secretory Phenotype, Senotherapeutics, Animals, Cell Line, Energy Metabolism, Flavonoids, Gene Expression Regulation, Humans, Longevity, Mitochondria, Cellular Senescence, Apoptosis, Oxidative Stress, Computational Biology, Gene Expression Profiling, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice. https://app.cochat.ai/papers/10.1038/s42255-021-00491-8
The paper
Xu, Q., Fu, Q., Li, Z., Liu, H., Wang, Y., Lin, X., He, R., Zhang, X., Ju, Z., Campisi, J., Kirkland, J. L., & Sun, Y. (2021). The flavonoid procyanidin C1 has senotherapeutic activity and increases lifespan in mice. Nature Metabolism. https://doi.org/10.1038/s42255-021-00491-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.